Zevin Asset Management LLC Lowers Stock Holdings in Pfizer Inc. (NYSE:PFE)

Zevin Asset Management LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 8,810 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. Zevin Asset Management LLC’s holdings in Pfizer were worth $317,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Morgan Stanley raised its holdings in Pfizer by 2.4% in the 2nd quarter. Morgan Stanley now owns 46,536,777 shares of the biopharmaceutical company’s stock worth $2,015,972,000 after acquiring an additional 1,071,897 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Pfizer by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 45,291,398 shares of the biopharmaceutical company’s stock worth $1,627,320,000 after acquiring an additional 1,158,147 shares during the last quarter. Nuveen Asset Management LLC raised its holdings in Pfizer by 2,240.5% in the 2nd quarter. Nuveen Asset Management LLC now owns 36,086,254 shares of the biopharmaceutical company’s stock worth $1,563,256,000 after acquiring an additional 34,544,423 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Pfizer by 2.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 35,948,881 shares of the biopharmaceutical company’s stock worth $1,557,306,000 after acquiring an additional 868,839 shares during the last quarter. Finally, California Public Employees Retirement System raised its holdings in Pfizer by 5.3% in the 2nd quarter. California Public Employees Retirement System now owns 23,186,244 shares of the biopharmaceutical company’s stock worth $1,004,428,000 after acquiring an additional 1,159,857 shares during the last quarter. Hedge funds and other institutional investors own 71.52% of the company’s stock.

A number of research firms have commented on PFE. Bank of America began coverage on shares of Pfizer in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 target price for the company. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 target price for the company in a research report on Wednesday, August 28th. Morgan Stanley cut their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 27th. ValuEngine raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Credit Suisse Group reaffirmed a “hold” rating and issued a $41.30 target price on shares of Pfizer in a research report on Wednesday. Nine equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $44.02.

Shares of PFE stock traded up $0.14 during mid-day trading on Friday, reaching $37.05. 24,924,227 shares of the company’s stock traded hands, compared to its average volume of 23,366,957. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The firm has a 50 day moving average price of $36.62 and a two-hundred day moving average price of $39.26. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The firm has a market capitalization of $207.30 billion, a PE ratio of 12.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The firm had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $12.37 billion. During the same quarter in the previous year, the firm posted $0.78 EPS. The company’s revenue for the quarter was down 4.6% compared to the same quarter last year. As a group, equities analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date is Thursday, November 7th. Pfizer’s payout ratio is 48.00%.

In other Pfizer news, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average price of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Scott Gottlieb bought 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the acquisition, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What does earnings per share mean?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.